In today’s world, when a company takes the next step is just as important as the strides the company takes. This is especially the case when it comes to the pharmaceutical industry. Drugs in high demand appearing at exactly the right time have the ability to benefit the business as well as patients. Changes in the infrastructure of a business at exactly the right time have the ability to promote growth, which ultimately benefits the patients. Oncolix, Inc. is proving this is the case.

Who is Oncolix, Inc.

Oncolix, Inc. (OTC: AEPP) is a biotechnology company developing the drug, Prolanta™. This particular medication is a treatment for uterine, breast, ovarian and other cancers. As of now, the company has gained U.S. FDA clearance to proceed with human testing for the drug for the treatment of ovarian cancer. The Phase I clinical trial of Prolanta™ began in 2016 as a medication with an autophagy mechanism of action. The FDA granted the drug Orphan Drug status as a treatment for ovarian cancer. Evidence has shown strong support for the drug’s ability to help the body fight gynecological cancers and breast cancer. Evidence also supports its use as a treatment for prostate cancer as well. As of now, no signs of serious adverse reactions have been observed, which sets Prolanta™ apart from other drugs on the market used in the treatment of cancer.

Changes in Oncolix’s Branding

Oncolix, Inc. recently changed its name from Advanced Environmental Petroleum Producers Inc. to Oncolix, Inc. as a result of the company’s shift in focus to therapeutic treatments for cancer. Oncolix, Inc. also filed the necessary request with the Financial Industry Regulatory Authority (FINRA) to change the company’s stock symbol to reflect the company’s new name.

Changes in Oncolix’s Structure

Oncolix, Inc. isn’t just taking steps to rebrand itself as a biotechnological company. The company is altering its business structure. On October 4, 2017, Oncolix reported it’s increasing its number of directors from two to three. The directors will serve until reelection or if stockholder’s take action to change the current lineup of directors. Additionally, Jerry R. Youkey, M.D. and Dale Zajicek have been elected to serve on Oncolix’s board of directors. Zajicek is the company’s first independent board member. Since 2007, both Dr. Youkey and Mr. Zajicek have served as directors for Oncolix. One of the directors of the company, J. Donald Payne, resigned from his position but will continue to remain with the company as a secretary. Michael T. Redman is the chief executive officer of the company and will continue to serve as the company’s third director.

In the future, Oncolix will be adding an independent fourth director to meet OTC-QB requirements. One of the objectives of these changes is to fulfill the requirement of OTC-QB, which requires a company to have at least two independent directors. These changes would also help qualify Oncolix, Inc. for a NASDAQ listing (majority of directors must be independent). Appointing Zajicek as an independent director serves these purposes and will assist the company in meeting its goals.These directors bring a wealth of wisdom, experience and guidance that’ll allow Oncolix, Inc. to not only bring new hope to those with cancer but possibly change the future of cancer treatment.

Meet the Directors

In 1998, Jerry R. Youkey, M.D. became part of the Greenville Health System (GHS). Currently, he’s the executive vice president and chief academic officer. The GHS is an eight-campus system facilitated with 1,756 beds and over 14,000 employees, 1,000 of which are medical doctors. Dr. Youkey continues to serve as the founding dean of the University of South Carolina School of Medicine Greenville. In 2015, he became the University of South Carolina Health Sciences Greenville’s associate provost.

Dr. Youkey’s impressive educational background began at Stanford University in Palo Alto, CA. He furthered his education at the Medical College of Wisconsin in Milwaukee, WI. He completed an internship and general surgery residency at the William Beaumont Army Medical Center, located in El Paso, TX. He completed a fellowship in peripheral vascular surgery at the Walter Reed Army Medical Center in Washington D.C. In 1984, he was honorably discharged from the U.S. Army. He earned the rank of Colonel, Medical Corps.

Dale Zajicek has spent over 37 years in the pharmaceutical and biotechnological industry. He reigned as the president of BioVectra, Inc. from 1995 until 2015 when he retired. In 2005, he was promoted to chief operating officer at the company, and from this position, he increased the company’s drug development efforts and was responsible for the business’ contract manufacturing. He filed numerous Drug Master Files (DMF) and New Drug (IND) applications. Mr. Zajicek led BioVectra in the development of the drug docetaxel, a generic drug used to treat various cancers including breast, prostate and non-small cell lung cancer. He obtained the “first to file” status for docetaxel. Previously, he managed the manufacturing operations as well as research, product development, business development and engineering at The NutraSweet Company and G.D. Searle. He possesses a bachelor of science in chemical engineering from the Illinois Institute of Technology. In addition, Mr. Zajicek possesses a bachelor’s degree in business administration from Elmhurst College.

About the Author

Stuart Smith is the CEO and Founder of SmallCapVoice.com. SmallCapVoice.com. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit https://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/